Skip to main content

Table 3 Day 4 and day 8 gametocyte prevalence adjusted for baseline gametocyte density

From: Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine

VariableGametocyte prevalence n/NOR (95% CI)p value
Day 4 prevalence
 AL only8/30Ref. 
 AL + primaquine day 14/350.28 (0.06 – 1.37)0.116
 AL + primaquine day 38/310.79 (0.21 – 3.00)0.726
Day 8 prevalence
 AL only4/30Ref. 
 AL + primaquine day 10/35
 AL + primaquine day 32/310.51 (0.07 – 3.60)0.502
  1. AL artemether–lumefantrine, OR odds ratio, CI confidence interval